α-npb

NPB (Alpha-NPB) is a potent BAD phosphorylation inhibitor(at Ser99,IC50 of 0.41 μM.)

NPB-1575 is a potent, orally active anti-inflammatory agent capable of crossing the blood-brain barrier. It mitigates neuroinflammation and resists ferroptosis by activating IRS2/Nrf2/NF-κB. NPB-1575 protects against cerebral ischemic injury and improves neurological function outcomes, making it suitable for research in focal ischemic stroke.

AzddMeC (Az-Dcme) is a nucleoside analog with antiviral activity and is an orally active and selective inhibitor of HIV-1 reverse transcriptase and HIV-1 replication.AzddMeC has an EC50 value of 9 nM against HIV-1-infected human PBM cells and 6 nM against HIV-1-infected human macrophages.

IT1t dihydrochloride inhibits CXCL12/CXCR4 interaction with IC50 of 2.1 nM. IT1t dihydrochloride is an antagonist of CXCR4.

Vicriviroc maleate (SCH-417690 (maleate))(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. The IC50 value is 0.91 nM in clinical development for the treatment of HIV-1.

3'-Azido-3'-deoxy-5-methylcytidine inhibits HIV-1 reverse transcriptase (EC50 = 0.06 μM) and is an effective inhibitor of xenotropic murine leukemia-related retrovirus [XMRV, CC50 = 43.5 μM].

Mavorixafor trihydrochloride is a selective and orally available CXCR4 antagonist (IC50: 13 nM against CXCR4 125I-SDF binding) and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs (IC50s: 1 and 9 nM).

Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2 with anti-inflammatory and antiinfective activity.

IT1t inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM. is a potent CXCR4 antagonist.

ML604440 is a cell permeable proteasome β1i (LMP2) subunit inhibitor.

TTNPB (Ro 13-7410,AGN-191183), a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.

AZD2906, a selective glucocorticoid receptor (GR) agonist, demonstrates inhibitory concentrations (IC50s) of 2.2 nM in human GR, 0.3 nM in rat peripheral blood mononuclear cells (PBMC), 41.6 nM in human whole blood, and 7.5 nM in rat whole blood, respectively[1]. Additionally, it induces an increase in micronucleated immature erythrocytes within rat bone marrow.

TAK-220 is a selective and orally bioavailable CCR5 antagonist with IC50 values of 3.5 nM for RANTES binding inhibition and 1.4 nM for MIP-1α binding inhibition to CCR5.

SNPB-sulfo-Me is a cleavable linker used in the development of antibody-drug conjugates (ADC).

SNPB is a cleavable linker utilized in the synthesis of antibody-drug conjugates (ADC).

Sulfo-SNPB is a cleavable linker used in the synthesis of antibody-drug conjugates (ADC).

AMD-070 hydrochloride is a CXCR4 antagonist, is useful for Anti HIV.

CYM 50769 is a neuropeptide W/B receptor 1 (NPBWR1, GPR7) antagonist(IC50 = 0.12 μM). CYM 50769 inhibited NPW activation of NPBWR1 with a submicromolar IC50, and displayed high selectivity against a broad array of off-targets with pharmaceutical relevance.

IL-2-IN-1 is a potent inhibitor of IL-2 (IC50: 1978 nM) and demonstrates anti-proliferative effects.

TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).

NPBA, a potassium K2P channel TASK-3 (KCNK9) agonist, concurrently functions as a blocker of the tandem pore domain weak inward rectifying K+ channel (TWIK2). This compound effectively inhibits NLRP3 inflammasome activation in macrophages [1].

NP-BTA, an allosteric inhibitor of glutaminyl-tRNA synthetase (GlnRS), demonstrates antifungal activity against Candida albicans, with a MIC50 of 6.25 μM [1].

Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.

Mavorixafor (AMD-070) is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM).